A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable mecA by a Commercial PCR Assay Compared to Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates
Keyword(s):
ABSTRACT mecA-positive Staphylococcus aureus isolates phenotypically susceptible to cefoxitin (mecA-methicillin-sensitive S. aureus [MSSA]) have been identified. We describe the treatment and outcomes among patients with mecA-MSSA bloodstream infections (BSI) and MRSA BSI matched 1:1 for age, BSI origin, and BSI type (n = 17 per group). Compared to MRSA BSI patients, mecA-MSSA BSI patients more often experienced clinical failure (58.8% and 11.8%, P = 0.010), driven largely by persistent bacteremia (35.3% and 11.8%). mecA-MSSA BSI patients may be at higher risk for poor clinical outcomes.
2019 ◽
Vol 6
(Supplement_2)
◽
pp. S769-S769
2011 ◽
Vol 56
(3)
◽
pp. 1258-1264
◽
2019 ◽
Vol 70
(8)
◽
pp. 1536-1545
◽
2013 ◽
Vol 57
(4)
◽
pp. 1998-2000
◽
2016 ◽
Vol 60
(10)
◽
pp. 5841-5848
◽
2021 ◽
Vol 8
◽
pp. 204993612110059